Please login first

The 2nd International Electronic Conference on Vaccines

Part of the International Electronic Conference on Vaccines series
27–29 Nov 2024
Event's Timezone: Central European Time
Abstract Submission Deadline
16th August 2024
Abstract Acceptance Notification
10th September 2024

Registration Deadline
24th November 2024

Immunology Mechanisms, Animal Models for Immunologic Diseases, Viral Immunology, Immunopathogenesis, Vaccine Development and Efficacy Evaluation, Immune Responses to Vaccines, Vaccine Technology, Vaccine Vectors Adjuvants and Immunomodulators
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us Become a Sponsor

IECV 2024 will be FREE for Participation!

Join us today to register and submit your abstract, and be part of cutting-edge discussions and networking opportunities!

Welcome from the Chair

We are pleased to announce the 2nd International Electronic Conference on Vaccines (IECV 2024), which will be held online and promoted by the open access MDPI journal Vaccines (ISSN 2076-393X, IF 7.8).

There are currently major challenges to developing new vaccines and improving existing platforms for both infectious diseases and cancer. Novel methods of vaccine delivery for both human and different animal species are required. Advances in vaccine design to give broad protection to mitigate against the mutation of antigens and to provide both good humoral and cellular immunity are a priority. For flaviviruses, particularly dengue, there are major hurdles to producing vaccines, which not only cover all the serotypes but also prevent the induction of antibody-dependent enhancement. Inactivated and subunit vaccines need to be combined with effective long-acting adjuvants to optimise their potential. In all cases, novel assays, in particular omics-based approaches, are necessary to evaluate in-depth and early responses to vaccination.

The IECV 2024 invites researchers from academia, as well as vaccine practitioners, to contribute original findings, novel ideas, scientific concepts, and new technologies and experiences to deal with immunology mechanisms, animal models for immunologic diseases, viral immunology, immunopathogenesis, vaccine development and efficacy evaluation, immune responses to vaccines, vaccine technology, vaccine vectors, adjuvants, and immunomodulators, with reference to the following topics:

Cancer vaccines, immunotherapy, and immunoprevention;
Challenges of developing a dengue vaccine;
Vaccine adjuvants;
mRNA vaccines;
Advancement in vaccine design for broad protection;
Novel assays for evaluating responses to vaccination.

The conference will be held entirely online, allowing people from all around the world to participate without any concerns about travel or related expenses. An electronic conference offers a platform for quick and direct exchanges of the latest research findings and innovative ideas.

The vaccine scientific community's support and enthusiasm are greatly appreciated, as you play a crucial role in ensuring the success of this 2nd edition of IECV. Your contribution will pave the way for many more successful editions in the future.

Kind regards,
Professor Sara Louise Cosby
School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK
Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, UK

Follow us on Social Media!

Event Chair

1. School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK,
2. Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, UK

Professor Sara Louise Cosby is a graduate (B.Sc. and Ph.D. in Microbiology, Queen’s University Belfast (QUB), a Fellow of the Royal College of Pathologists (speciality Virology) and Fellow of the Royal Society of Biology (RSB). Louise is Head of Virology at the Agri-Food and Biosciences Institute in Belfast and an honorary/emeritus Professor in the Wellcome Wolfson Institute for Experimental Medicine, in the School of Medicine Dentistry and Biomedical Sciences (MDBMS), QUB. She previously held the Chair of Microbiology in the School of MDBMS. As Head of Virology at AFBI, she oversees international research programmes and is responsible for virus molecular and immune diagnostics for epizootic animal diseases. Louise’s research has focused on elucidation of pathogenic mechanisms of measles virus, the closely related veterinary morbilliviruses and more recently bovine respiratory syncytial, herpes and corona viruses. Louise is currently on the Science Advisory Board of the Animal and Plant Health Agency, UK. She is a RSB Trustee/Council member and represents the RSB on the All-Party Group on STEM at the parliament at Stormont in Northern Ireland. Louise is also a member of the board of the BBSRC and DEFRA funded ‘UK International Coronavirus research and innovation network’.

Session Chairs

Prof. Dr. Silvio Tafuri

Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy

Prof. Dr. Martin J. D'Souza

Department of Pharmaceutical Sciences, Mercer University, Macon, USA

Prof. Dr. Mona O. Mohsen

Department of Biomedical Research, University of Bern, Bern, Switzerland

Dr. Jorge H. Leitão

Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal

Dr. Tan Yee Joo

Infectious Diseases Translational Research Programme and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Dr. Hatem A. Elshabrawy

Department of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Huntsville, USA

Assoc. Prof. Srinivasa Reddy Bonam

1. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA; 2. Bapatla College of Pharmacy, Bapatla, India

Prof. Dr. Seth Pincus

Department of Chemistry and Biochemistry, Montana State University, Bozeman, USA

Dr. Henry Nelson Puerta-Guardo

Virology Lab, CIR-Biomedicas, and Campus of Biological and Agricultural Sciences, Autonomous University of Yucatan, Mérida, Mexico

Dr. Bapi Pahar

Department of Microbiology and Immunology, Tulane University, New Orleans, USA

Event Committee

Department of Public Health Policy, School of Public Health, University of West Attica, Greece

Dimitris Zavras is Assistant Professor of Health Services Research and Health Economics at the Department of Public Health Policy at the University of West Attica. Along his academic, educational and research responsibilities he serves as Director of the Division of Health Systems and Policy. He is also Faculty Member of the Hellenic Open University. Dimitris was born in Athens in 1968 and studied Physics at the National & Kapodistrian University of Athens. His postgraduate studies include an M.Sc. in Applied Physics from the University of Massachusetts; M.Sc. in Statistics from Athens University of Economics and Business; M.Sc. in Healthcare Management from the National School of Public Health; and a Doctorate (Ph.D.) in Health Services Research and Health Economics from the University of Thessaly (Department of Economics). Dimitris has taught in postgraduate programs of the University of West Attica, the University of Peloponnese, the Neapolis University Pafos (Cyprus), and the National School of Public Health and in undergraduate programs of the University of West Attica, the University of Peloponnese and the Athens University of Applied Sciences. Dimitris Zavras’ research interests focus on healthcare access and economics, the utilization of healthcare services, healthcare provider choice, and unmet healthcare needs. His most recent research work and published articles deal with economic issues surrounding the COVID-19 pandemic. He is a member of the International Health Economics Association, the Hellenic Scientific Society of Health Economics and Health Policy and the Hellenic Society of Public Health. He is also a member of the Hellenic Society for Healthcare Services Management.

Department of Biomedicine and Prevention, University of Rome, Rome, Italy

Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milano, Italy

Department of Medical Sciences, University of Ferrara, Ferrara, Italy

1. School of Human Sciences, London Metropolitan University, London, UK;,
2. National Heart and Lung Institute, Imperial College London, London, UK

Physician-Scientist, New York, USA

Department of Veterinary Microbiology, Western College of Veterinary Medicine, Saskatoon, Canada

Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

College of Pharmacy, University of Illinois, Chicago, USA

Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Ferrara, Italy

Department of Animal Health, University of Córdoba, Cordoba, Spain

Department of Pharmacology, University of Minnesota, Minnesota, USA

Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, USA

IrsiCaixa AIDS Research Institute, Badalona, Spain

EA4340-BCOH: Biomarker in Cancerology and Onco-Haematology, Université de Versailles Saint- Quentin-En-Yvelines, Boulogne-Billancourt, France

Department of Veterinary Biosciences, The Ohio State University, Columbus, USA

Department of Pharmacology, University of Minnesota, Minnesota, USA

Molecular Pharmacology Program, Laboratory of Signal Transduction, Mortimer B. Zuckerman Research Center, Memorial Sloan Kettering Cancer Center New York, USA

Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, USA

Department of Electrical and Computer Engineering, Iowa State University, Iowa, USA

Division of Biomedical and Life Sciences, Furness College, Lancaster University, Lancaster, UK

Department of Radiology, Michigan State University, East Lansing, USA

Protheragen Inc., Holbrook, New York, USA

Laboratory of Microbiology, Democritus University of Thrace, Komotini, Greece

School of Humanities and Social Sciences, Waseda University, Tokyo, Japan

School of Medical and Life Sciences, Sunway University, Selangor, Malaysia

1. Department of Public Health, School of Health Sciences, Ashkelon Academic College, Ashkelon, Israel;,
2. School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheba, Israel

Department of Women's and Children's Health, K6 Karolinska Institute, Stockholm, Sweden

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA

Department of Medicine, Amedeo Avogadro University of Eastern Piedmont, Piedmont, Italy

Vector Biology Section, Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA

Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, Tampa, USA

Department of Biomedical Sciences, University of Sassari, Sassari, Italy

Keynote Speakers

University of Texas Health Science Center’s Institute of Molecular Medicine (IMM) , USA

Prof. Eva M. Sevick, Ph.D. is At the IMM she leads the National Cancer Institute Center for Translational Research which focuses upon the development and validation of new imaging instrumentation, algorithms, and imaging agents and their clinical translation. She has pioneered the development of near-infrared fluorescence optical imaging and tomography for molecular imaging and currently has two clinical trials underway at the University of Texas Health Science Center and Memorial Hermann Hospital that employ the technology for novel diagnostic imaging of lymphatic function. Her team is active in preclinical, small animal imaging with nuclear and optical techniques and is pioneering diagnostic imaging for nodal staging in cancer. Dr. Sevick received her Ph.D. in Chemical Engineering at Carnegie Mellon University with Rakesh Jain, her post-doctoral training in Biochemistry and Biophysics at the University of Pennsylvania with Britton Chance, and has served on the faculties at Vanderbilt, Purdue, Texas A&M as well as Baylor College of Medicine. She is past recipient of the National Science Foundation Young Investigator Award, the National Institutes of Health Research Career Award, and the American Cancer Society Research Scholar Award and has served as an appointed member of the Biomedical Imaging Study section, associate editor of the IEEE Transactions of Medical Imaging, and officer of the Society of Molecular Imaging.

1. Department of Immunology, University of Bern, Bern, Switzerland,
2. Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK

Martin Bachmann studied Cell Biology at the ETH Zürich. In 1995, he earned his PhD Immunology from the ETH Zürich in Switzerland under the supervision of Prof. Zinkernagel in Zürich followed by a Post-Doc at the laboratory of Prof. Ohashi in Canada. After working as a member at the Basel Institute for Immunology and running research at a Biotech company for 10 years, Martin Bachmann became a faculty member and full professor at the University of Bern. Martin is currently professor at the University of Bern and University of Oxford.

Invited Speakers

Institute of Research in Biomedicine, Universita della Svizzera italiana, Switzerland

Roger Geiger obtained his Master’s and PhD degrees from ETH Zürich. During his PhD studies with Ari Helenius, he investigated how non-enveloped viruses penetrate host cell membranes. He then joined Antonio Lanzavecchia’s laboratory at the Institute for Research in Biomedicine (IRB) as a SystemsX postdoctoral fellow, focusing on the metabolic regulation of T cell responses. In 2016, Roger joined Matthias Mann’s research group at the Max Planck Institute of Biochemistry in Munich, where he received training in mass spectrometry-based proteomics. In 2017, he established his research group at the IRB, aiming to study immune responses to tumors using systems biology approaches. He is Associate Professor at USI, EMBO Young Investigator, and has been awarded an ERC Starting Grant and a Consolidator Grant.

Department of Immunology, University of Bern, Bern, Switzerland


The registration for IECV 2024 will be free of charge! The registration includes attendance to all conference sessions.

If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.

Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 24th November 2024.

Instructions for Authors

Procedure for Submission

IECV 2024 will accept abstracts only. The accepted abstracts will be available online on during and after the conference.

Important Deadlines
- Deadline for abstract submission: 16 August 2024.
- Announcement of oral and poster abstract results: 10 September 2024. You will be notified of the acceptance of an oral/poster presentation in a separate email.

Certificates of Participation are available in your logged-in area of, under “My Certificates” after the conference.

Abstract Submission
Abstract submissions should be completed online by registering with and using the "Submit Abstract" function on conference homepage. No physical template is necessary.

1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
3. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
4. The abstracts submitted to this conference must be original and novel, without prior publication in any journals or it will not be accepted to this conference.

Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
Oral Presentation and Slides Submission
The slot for the oral presentation is 15 mins. We advise that your presentation lasts for a maximum of 12 mins, leaving at least 3 mins for the Q&A session. Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the abstract. Slides, if available, will be displayed directly on the website using the proprietary slide viewer at Slides can be prepared in exactly the same way as for any traditional conference where research results are presented. Slides should be converted to PDF format prior to submission so that they can be converted for online display.
Poster Presentation

- Poster should include the title, authors, contact details and main research findings, as well as tables, figures and graphs where necessary.
- File format: PDF (.pdf).
- Size in pixel: 1080 width x 1536 height–portrait orientation.
- Size in cm: 38,1 width x 54,2 height–portrait orientation.
- Font size: ≥16.Examples of successful submissions can be viewed here at the following links: (1), (2), (3).

You can use our free template to create your poster. The poster template can be downloaded HERE.

The Poster Sessions will take place in Zoom break-out rooms. The rooms will be called after your surname. You will automatically be assigned to your break-out room, however, you will be responsible for your own room, i.e. sharing your screen by yourself, handling the comments in the chat if there are any, etc. People will then be able to visit your room and discuss your poster with you. Please make sure you have the Zoom Desktop client or mobile app, version 5.3.0 or higher.

We will reach out to you closer to the dates of the conference with more information.

Potential Conflicts of Interest

It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.


MDPI, the publisher of the platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.

Publication Opportunities

1. Vaccines Journal Publication
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue (to be updated), published in Vaccines (ISSN 2076-393X, Impact Factor 7.8), with a 10% discount on the publication fee. Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
2. Proceeding Paper Publication
All accepted abstracts will be published in the conference report of The 2nd International Electronic Conference on Vaccines in Medical Sciences Forum (ISSN: 2673-9992); if you wish to publish an extended proceeding paper (4-8 pages), please submit it to the same journal after the conference.
Authors are asked to disclose that it is a proceeding paper of the IECV 2024 conference paper in their cover letter. Carefully read the rules outlined in the 'Instructions for Authors' on the journal’s website and ensure that your submission adheres to these guidelines.

Proceedings submission deadline: 15 January 2025.

Manuscripts for the proceedings issue must be formatted as follows:
Full author names.
Affiliations (including full postal address) and authors' e-mail addresses.
Results and Discussion.

IECV 2024 Proceeding Paper Template

Event Awards

To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 6 awards including Best Oral Presentation Awards and Best Poster Awards.

The Awards
Best Oral Presentation Awards and Best Poster Awards

Number of Awards Available: 6

The Best Oral Presentation Awards are given to the paper judged to make the most significant oral contribution to the conference.
The Best Poster Awards are given to the submission judged to make the most significant and interesting poster for the conference.

There will be six winners selected for these awards. The winner will receive a certificate and 200 CHF each.

Sponsors and Partners

For information regarding sponsorship and exhibition opportunities, please click here.


Media Partners

Conference Secretariat

Ms. Amy Chen
Ms. Cynthia Wang

Ms. Theodora Felegean

For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.